Comparison of Covid-19 antibody status after vaccination between residents in long-term geriatric care and residents assisted-living facilities

Jochanan E. Naschitz; Jennifer Kertes; Galit Pinto; Natalia Zaigraykin; Dana Oz; Ella Goland; Shuruk Nasser; Lia Supino-Rosin; Rachel Lazar; Anat Ekka-Zohar

doi:10.1080/23744235.2021.2014559

Comparison of Covid-19 antibody status after vaccination between residents in long-term geriatric care and residents assisted-living facilities

Jochanan E. Naschitz, Jennifer Kertes, Galit Pinto, Natalia Zaigraykin, Dana Oz, Ella Goland, Shuruk Nasser, Lia Supino-Rosin, Rachel Lazar, Anat Ekka-Zohar

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To compare 2 CoV-SARS-2 (‘anti-s’) antibody levels after vaccination between residents in long-term geriatric care (LTGC) and residents in assisted-living facilities who had received two doses of the BNT162b2 vaccine. SARS-CoV-2 serology was tested with Quant II IgG CoV-SARS-2. Blood samples were collected 3–4 months after administration of the second vaccine dose. Results: Anti-s ≥ 50 AU/ml was found in 85.4% of 90 residents in LTGC (median 498 AU/ml) and 94.9% of 214 residents in assisted living (median 728 AU/ml). p =.006. Factors associated with anti-s < 300 AU/ml were multi-morbidity, diabetes mellitus and cancer.

Original language	English
Pages (from-to)	292-296
Number of pages	5
Journal	Infectious Diseases
Volume	54
Issue number	4
DOIs	https://doi.org/10.1080/23744235.2021.2014559
State	Published - Apr 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2021 Society for Scandinavian Journal of Infectious Diseases.

Keywords

BNT162b2 vaccine
Covid-19
elderly
geriatric care
serology

ASJC Scopus subject areas

General Immunology and Microbiology
Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/23744235.2021.2014559

Cite this

@article{402d44d3410041ce8f6c5a9b237e80a1,

title = "Comparison of Covid-19 antibody status after vaccination between residents in long-term geriatric care and residents assisted-living facilities",

abstract = "Objective: To compare 2 CoV-SARS-2 ({\textquoteleft}anti-s{\textquoteright}) antibody levels after vaccination between residents in long-term geriatric care (LTGC) and residents in assisted-living facilities who had received two doses of the BNT162b2 vaccine. SARS-CoV-2 serology was tested with Quant II IgG CoV-SARS-2. Blood samples were collected 3–4 months after administration of the second vaccine dose. Results: Anti-s ≥ 50 AU/ml was found in 85.4% of 90 residents in LTGC (median 498 AU/ml) and 94.9% of 214 residents in assisted living (median 728 AU/ml). p =.006. Factors associated with anti-s < 300 AU/ml were multi-morbidity, diabetes mellitus and cancer.",

keywords = "BNT162b2 vaccine, Covid-19, elderly, geriatric care, serology",

author = "Naschitz, {Jochanan E.} and Jennifer Kertes and Galit Pinto and Natalia Zaigraykin and Dana Oz and Ella Goland and Shuruk Nasser and Lia Supino-Rosin and Rachel Lazar and Anat Ekka-Zohar",

note = "Publisher Copyright: {\textcopyright} 2021 Society for Scandinavian Journal of Infectious Diseases.",

year = "2022",

month = apr,

doi = "10.1080/23744235.2021.2014559",

language = "English",

volume = "54",

pages = "292--296",

journal = "Infectious Diseases",

issn = "2374-4235",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Comparison of Covid-19 antibody status after vaccination between residents in long-term geriatric care and residents assisted-living facilities

AU - Naschitz, Jochanan E.

AU - Kertes, Jennifer

AU - Pinto, Galit

AU - Zaigraykin, Natalia

AU - Oz, Dana

AU - Goland, Ella

AU - Nasser, Shuruk

AU - Supino-Rosin, Lia

AU - Lazar, Rachel

AU - Ekka-Zohar, Anat

PY - 2022/4

Y1 - 2022/4

N2 - Objective: To compare 2 CoV-SARS-2 (‘anti-s’) antibody levels after vaccination between residents in long-term geriatric care (LTGC) and residents in assisted-living facilities who had received two doses of the BNT162b2 vaccine. SARS-CoV-2 serology was tested with Quant II IgG CoV-SARS-2. Blood samples were collected 3–4 months after administration of the second vaccine dose. Results: Anti-s ≥ 50 AU/ml was found in 85.4% of 90 residents in LTGC (median 498 AU/ml) and 94.9% of 214 residents in assisted living (median 728 AU/ml). p =.006. Factors associated with anti-s < 300 AU/ml were multi-morbidity, diabetes mellitus and cancer.

AB - Objective: To compare 2 CoV-SARS-2 (‘anti-s’) antibody levels after vaccination between residents in long-term geriatric care (LTGC) and residents in assisted-living facilities who had received two doses of the BNT162b2 vaccine. SARS-CoV-2 serology was tested with Quant II IgG CoV-SARS-2. Blood samples were collected 3–4 months after administration of the second vaccine dose. Results: Anti-s ≥ 50 AU/ml was found in 85.4% of 90 residents in LTGC (median 498 AU/ml) and 94.9% of 214 residents in assisted living (median 728 AU/ml). p =.006. Factors associated with anti-s < 300 AU/ml were multi-morbidity, diabetes mellitus and cancer.

KW - BNT162b2 vaccine

KW - Covid-19

KW - elderly

KW - geriatric care

KW - serology

UR - http://www.scopus.com/inward/record.url?scp=85121704405&partnerID=8YFLogxK

U2 - 10.1080/23744235.2021.2014559

DO - 10.1080/23744235.2021.2014559

M3 - Article

C2 - 34918582

AN - SCOPUS:85121704405

SN - 2374-4235

VL - 54

SP - 292

EP - 296

JO - Infectious Diseases

JF - Infectious Diseases

IS - 4

ER -

Comparison of Covid-19 antibody status after vaccination between residents in long-term geriatric care and residents assisted-living facilities

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this